News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Aoxing Pharmaceutical Company Inc. (AXN) to Present at Jefferson Medical College's 2010 Global SpecPharma and European Healthcare Conference

9/27/2010 8:27:59 AM

NEW YORK, NY--(Marketwire - September 27, 2010) - Aoxing Pharmaceutical (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced that the Company will be presenting at the Jefferies' 2010 Global SpecPharma and European Healthcare Conference in London, United Kingdom.

The Aoxing Pharma will present at 9:00 AM BST on October 06, 2010 at the Waldorf Hilton, London. A live webcast and 90-day archive of the presentation will be available at

Dr. David Shao, CFO will provide a review of recent pipeline developments, international collaborations and financial progress at Aoxing Pharma.

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has a joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. It also has strategic alliance partnership with QRxPharma, Phoenix PharmaLabs, Inc and American Oriental Bioengineering, Inc. For more information, please visit:

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended June 30, 2009, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Aoxing Pharmaceutical Co., Inc.
David Shao
Chief Financial Officer
646- 367-1747

Investor Relations:
The Trout Group
Brian Korb

Read at

Related News

comments powered by Disqus